Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGG492 in refractory partial onset seizures
NCT01167335Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Aug 2010
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in focal onset seizure comparing BGG492 + AEDs with Placebo + AEDs (2 arms). Primary endpoint: Percent change in seizure frequency at 28 days. Planned start Aug 2010; status: withdrawn.
02
Drugs
selurampanel
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT01167335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01167335.